JSPR vs. DCGO, AVXL, CRBU, MGTX, SOPH, TNYA, CADL, BDTX, IVVD, and ADAP
Should you be buying Jasper Therapeutics stock or one of its competitors? The main competitors of Jasper Therapeutics include DocGo (DCGO), Anavex Life Sciences (AVXL), Caribou Biosciences (CRBU), MeiraGTx (MGTX), SOPHiA GENETICS (SOPH), Tenaya Therapeutics (TNYA), Candel Therapeutics (CADL), Black Diamond Therapeutics (BDTX), Invivyd (IVVD), and Adaptimmune Therapeutics (ADAP). These companies are all part of the "medical" sector.
DocGo (NASDAQ:DCGO) and Jasper Therapeutics (NASDAQ:JSPR) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their valuation, earnings, community ranking, media sentiment, profitability, analyst recommendations, risk, institutional ownership and dividends.
DocGo presently has a consensus target price of $7.75, suggesting a potential upside of 155.78%. Jasper Therapeutics has a consensus target price of $64.29, suggesting a potential upside of 183.07%. Given DocGo's higher possible upside, analysts clearly believe Jasper Therapeutics is more favorable than DocGo.
56.4% of DocGo shares are owned by institutional investors. Comparatively, 79.9% of Jasper Therapeutics shares are owned by institutional investors. 13.8% of DocGo shares are owned by company insiders. Comparatively, 2.7% of Jasper Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
DocGo has a beta of 0.96, suggesting that its stock price is 4% less volatile than the S&P 500. Comparatively, Jasper Therapeutics has a beta of 2.25, suggesting that its stock price is 125% more volatile than the S&P 500.
DocGo has higher revenue and earnings than Jasper Therapeutics. Jasper Therapeutics is trading at a lower price-to-earnings ratio than DocGo, indicating that it is currently the more affordable of the two stocks.
DocGo received 15 more outperform votes than Jasper Therapeutics when rated by MarketBeat users. However, 83.87% of users gave Jasper Therapeutics an outperform vote while only 73.21% of users gave DocGo an outperform vote.
DocGo has a net margin of 2.98% compared to DocGo's net margin of 0.00%. Jasper Therapeutics' return on equity of 6.20% beat DocGo's return on equity.
In the previous week, Jasper Therapeutics had 16 more articles in the media than DocGo. MarketBeat recorded 27 mentions for Jasper Therapeutics and 11 mentions for DocGo. DocGo's average media sentiment score of 0.81 beat Jasper Therapeutics' score of 0.65 indicating that Jasper Therapeutics is being referred to more favorably in the news media.
Summary
DocGo beats Jasper Therapeutics on 9 of the 16 factors compared between the two stocks.
Get Jasper Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for JSPR and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding JSPR and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Jasper Therapeutics Competitors List
Related Companies and Tools
